[go: up one dir, main page]

BRPI0410972A - método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia - Google Patents

método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia

Info

Publication number
BRPI0410972A
BRPI0410972A BRPI0410972-4A BRPI0410972A BRPI0410972A BR PI0410972 A BRPI0410972 A BR PI0410972A BR PI0410972 A BRPI0410972 A BR PI0410972A BR PI0410972 A BRPI0410972 A BR PI0410972A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
extending
shelf life
treating hyperglycemia
peptide
Prior art date
Application number
BRPI0410972-4A
Other languages
English (en)
Inventor
Claus Juulmortensen
Dorte Kot Engelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/DK2004/000380 external-priority patent/WO2004105781A2/en
Publication of BRPI0410972A publication Critical patent/BRPI0410972A/pt
Publication of BRPI0410972B1 publication Critical patent/BRPI0410972B1/pt
Publication of BRPI0410972B8 publication Critical patent/BRPI0410972B8/pt
Publication of BRPI0410972C1 publication Critical patent/BRPI0410972C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA AUMENTAR A VIDA DE ARMAZENAGEM DE UMA COMPOSIçãO FARMACêUTICA, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA TRATAMENTO DE HIPERGLICEMIA". Método para aumentar a vida de armazenagem de uma composição farmacêutica para administração parenteral compreendendo um peptídeo semelhante a glucagon que é preparado a partir de um produto de peptídeo que tem sido submetido ao tratamento em um pH acima de pH neutro.
BRPI0410972A 2003-06-03 2004-06-03 método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia BRPI0410972C1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200300819 2003-06-03
DKPA200300819 2003-06-03
DKPA200400075 2004-01-19
DKPA200400075 2004-01-19
PCT/DK2004/000380 WO2004105781A2 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions

Publications (4)

Publication Number Publication Date
BRPI0410972A true BRPI0410972A (pt) 2006-07-04
BRPI0410972B1 BRPI0410972B1 (pt) 2018-01-30
BRPI0410972B8 BRPI0410972B8 (pt) 2018-12-04
BRPI0410972C1 BRPI0410972C1 (pt) 2021-05-25

Family

ID=36645905

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410972A BRPI0410972C1 (pt) 2003-06-03 2004-06-03 método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia

Country Status (8)

Country Link
US (2) US7632806B2 (pt)
EP (1) EP2292254A3 (pt)
JP (1) JP4936884B2 (pt)
KR (1) KR101308912B1 (pt)
CN (1) CN102940879B (pt)
AT (1) ATE541582T1 (pt)
BR (1) BRPI0410972C1 (pt)
ES (1) ES2380437T3 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
KR100746658B1 (ko) 2007-04-23 2007-08-06 성균관대학교산학협력단 소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US20110034385A1 (en) * 2008-04-07 2011-02-10 National Institute Of Immunology Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US9445992B2 (en) 2009-11-25 2016-09-20 Arisgen Sa Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
RU2557301C2 (ru) * 2010-05-17 2015-07-20 Бетта Фармасьютикалз Ко.,Лтд Новые аналоги глюкагон-подобного пептида, композиция и способ применения
US8636711B2 (en) * 2010-06-14 2014-01-28 Legacy Emanuel Hospital & Health Center Stabilized glucagon solutions and uses therefor
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211231A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives
MY180276A (en) * 2013-06-28 2020-11-26 Amgen Inc Stable liquid formulation of amg 416 (velcalcetide)
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
KR20170021313A (ko) * 2014-06-25 2017-02-27 글락소스미스클라인 엘엘씨 제약 조성물
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI814219B (zh) 2016-05-16 2023-09-01 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
KR102568413B1 (ko) 2017-06-15 2023-08-21 한국전자통신연구원 이온 빔 치료장치
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
CA3165355A1 (en) 2020-02-18 2021-07-22 Tommy SANDER Pharmaceutical formulations
WO2021219710A1 (en) * 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4281039A2 (en) 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
CN118307645A (zh) * 2021-05-28 2024-07-09 广东众生睿创生物科技有限公司 多肽的制备及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP2818176B2 (ja) 1987-05-14 1998-10-30 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガナイゼーション ホエー蛋白フラクション
JPH03505401A (ja) 1988-06-27 1991-11-28 ジェネックス・コーポレーション 組換えタンパク質の培養培地への熱放出
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
ATE147619T1 (de) 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
JPH09505290A (ja) 1993-11-19 1997-05-27 ジー．ディー．サール アンド カンパニー Ｎ‐［Ｎ‐［５‐［４‐（アミノイミノメチル）フェニル］‐１‐オキソペンチル］‐Ｌ‐α‐アスパルチル］‐Ｌ‐フェニルアラニンまたはそのエステル並びにそれらの医薬的に許容される塩類の経皮的組成物
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
DE69532492T2 (de) 1994-08-31 2004-12-02 Mitsubishi Pharma Corp. Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (ja) 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１組成物
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
EP0828753B1 (en) 1995-06-02 2003-03-26 Novozymes A/S Al/Fe-TREATMENT OF A PROTEIN SOLUTION, FOLLOWED BY MEMBRANE CONCENTRATION
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
RU2180218C2 (ru) 1997-01-20 2002-03-10 Джапэн Энерджи Корпорейшн Способ стабилизации гирудина и/или вариантов гирудина, лиофилизированная фармацевтическая композиция, полученная с применением данного способа
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
DE69738333T2 (de) 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
ATE237636T1 (de) 1997-10-24 2003-05-15 Genentech Inc Reinigung von molekülen
AU1617399A (en) * 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
ATE269103T1 (de) * 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
IL143346A0 (en) 1998-12-07 2002-04-21 Sod Conseils Rech Applic Analogues of glp-1
ATE307603T1 (de) * 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
ES2244416T5 (es) 1999-01-14 2020-01-03 Amylin Pharmaceuticals Llc Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
AU777570B2 (en) 1999-12-16 2004-10-21 Eli Lilly And Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
BR0107837A (pt) 2000-01-27 2003-01-14 Lilly Co Eli Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2001077141A1 (en) 2000-04-06 2001-10-18 Novo Nordisk A/S Shock heat treatment of polypeptides
DZ3388A1 (fr) 2000-06-16 2001-12-27 Lilly Co Eli Analogues de peptide 1 du type glucagon
CN1340549A (zh) * 2000-08-26 2002-03-20 徐州万邦生化制药有限公司 一种胰高血糖素制备工艺
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
PT1360202E (pt) * 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
MXPA04001525A (es) 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
JP2005526084A (ja) 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
DE60321473D1 (de) 2002-09-25 2008-07-17 Novo Nordisk As Aufreinigungsverfahren, das eine mikrofiltration bei erhöhten temperaturen beinhaltet
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2527743A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP4800959B2 (ja) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー／エス 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration

Also Published As

Publication number Publication date
BRPI0410972C1 (pt) 2021-05-25
KR101308912B1 (ko) 2013-09-23
EP2292254A3 (en) 2011-12-14
US20060178304A1 (en) 2006-08-10
US20100056451A1 (en) 2010-03-04
BRPI0410972B8 (pt) 2018-12-04
US7632806B2 (en) 2009-12-15
EP2292254A2 (en) 2011-03-09
ES2380437T3 (es) 2012-05-11
KR20120130264A (ko) 2012-11-29
US8614181B2 (en) 2013-12-24
BRPI0410972B1 (pt) 2018-01-30
ATE541582T1 (de) 2012-02-15
JP2008500262A (ja) 2008-01-10
JP4936884B2 (ja) 2012-05-23
CN102940879A (zh) 2013-02-27
CN102940879B (zh) 2017-06-06

Similar Documents

Publication Publication Date Title
BRPI0410972A (pt) método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
MXPA05013048A (es) Composiciones peptodicas farmaceuticas estabilizadas.
TW200745037A (en) Organic compounds
EA200401525A1 (ru) Способы лечения гепатита (варианты )
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
MY147489A (en) Methods for the treatment of muscle loss
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
EA200401365A1 (ru) Способы лечения илеуса
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60126829D1 (de) Kombination von drei Substanzen zur Vorbeugung und Behandlung von Arthritis
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
WO2006113718A3 (en) Compositions for the treatment of neoplasms
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/01/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REF. RPI 2456 DE 30/01/2018 QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.005341/2022-66 ORIGEM: 3A VARA FEDERAL CIVEL DA SJDF PROCESSO NO: 1089024-07.2021.4.01.3400 ACAO PELO PROCEDIMENTO COMUM AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL